Chimerism and cure: Hematologic and pathologic correction of murine sickle cell disease

Blood

Volumn 102, Issue 13, 2003, Pages 4582-4593

  Kean, Leslie S ^b   Manci, Elizabeth A ^b   Perry, Jennifer ^b   Balkan, Can ^b   Coley, Shana ^b   Holtzclaw, David ^b   Adams, Andrew B ^b   Larsen, Christian P ^b   Hsu, Lewis L ^b   Archer, David R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL SUBPOPULATION; CELL SURVIVAL; CHIMERA; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HALF LIFE TIME; HEMATOPOIESIS; LEUKOCYTE; MALE; MOUSE; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SUBSTITUTION THERAPY; TREATMENT OUTCOME; URINE OSMOLALITY;

EID: 10744229369     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-03-0712     Document Type: Article

References (30)

1. Walters MC, Patience M, Leisenring W, et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 1996;2:100-104.
2. Walters MC, Patience M, Leisenring W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7:665-673.
3. Eckman JR. Techniques for blood administration in sickle cell patients. Semin Hematol. 2001;38:23-29.
4. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000;95:1918-1924.
5. Adams AB, Durham MM, Kean L, et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol. 2001;167:1103-1111.
6. Kean LS, Durham MM, Adams AB, et al. Acute for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood. 2002;99:1840-1849.
7. Kean LS, Brown LE, Nichols JW, et al. Comparison of mechanisms of anemia in mice with sickle cell disease and beta-thalassemia: peripheral destruction, ineffective erythropoiesis, and phospholipid scramblase-mediated phosphatidylserine exposure. Exp Hematol. 2002;30:394-402.
8. de Jong K, Emerson RK, Butler J, Bastacky J, Mohandas N, Kuypers FA. Short survival of phosphatidylserine-exposing red blood cells in murine sickle cell anemia. Blood. 2001;98:1577-1584.
9. Iannone R, Luznik L, Engstrom LW, et al. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood. 2001;97:3960-3965.
10. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278:876-878.
11. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 1997;407:313-319.
12. Zhao Y, Lin Y, Zhan Y, et al. Murine hematopoietic stem cell characterization and its regulation in BM transplantation. Blood. 2000;96:3016-3022.
13. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001;98:3261-3273.
14. Kina T, Ikuta K, Takayama E, et al. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol. 2000;109:280-287.
15. Christian JA, Rebar AH, Boon GD, Low PS. Methodologic considerations for the use of canine in vivo aged biotinylated erythrocytes to study RBC senescence. Exp Hematol. 1996;24:82-88.
16. Tait JF, Gibson D. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med. 1994;123:741-748.
17. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood. 1996;88:1873-1880.
18. de Jong K, Larkin SK, Styles LA, Bookchin RM, Kuypers FA. Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. Blood. 2001;98:860-867.
19. Setty BN, Kulkarni S, Stuart MJ. Role of erythrocyte phosphatidyiserine in sickle red cell-endothelial adhesion. Blood. 2002;99:1564-1571.
20. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood. 2001;98:3228-3233.
21. Setty BN, Stuart MJ. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood. 1996;88:2311-2320.
22. Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol. 1996;81:96-98.
23. Hebbel RP. Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Engl J Med. 2000;342:1910-1912.
24. Makis AC, Hatzimichael EC, Bourantas KL. The role of cytokines in sickle cell disease. Ann Hematol. 2000;79:407-413.
25. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337-338.
26. Platt OS. The acute chest syndrome of sickle cell disease. N Engl J Med. 2000;342:1904-1907.
27. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med. 2000;6:464-469.
28. Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med. 1997;3:783-787.
29. Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med. 1998;187:2037-2044.
30. Durham MM, Bingaman AW, Adams AB, et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol. 2000;165:1-4.